ShouTi secures $100M to hit biologic and peptide targets with small molecules


Image of heart and circulatory system

ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs small molecules intended to do the work of biologic and peptide drugs.

Leave a Reply